#3046
Incidence of Neuroendocrine Neoplasms Reported in England 2015-2017
Introduction:
Previously published UK Cancer Registry data showed incidence of Neuroendocrine Neoplasms rising between 2001 and 2015. This was higher than had been thought (Genus et al). We report more recent data with more accurate coding (ICD-O-3).
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
White B,
Bouvier C,
Genus T,
Rous B,
Srirajaskanthan R,
Keywords:
Epidemiology,
Neuroendocrine Neoplasia,
Incidence,
Prevalence,
population data,
histopathology,
#2078
Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses
Introduction:
In practice, many patients with NETs report a change in symptoms after starting somatostatin analogues (SSA’s). Many health professionals and NET patient advocates have noticed that some of the side effects experienced by patients are more common than patient information literature suggests. It is therefore important to ask what and how severe experiences are, and compare to literature, to help raise awareness amongst NET health professionals.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Whyand T,
Davies P,
Bouvier C,
Keywords:
B12,
SSA,
Side effects,
Fat soluble vitamins,
#2021
1-Year Survival Rates for Neuroendocrine Tumor Patients in England
Introduction:
Individual centres in the UK often report good survival rates for patients with neuroendocrine tumours (NETs), however national survival data has not been available.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Genus T
Authors:
Genus T,
Bouvier C,
Wong K,
Srirajaskanthan R,
Rous B,
Keywords:
Neuroendocrine cancer,
survival,
grade,
stage,
age,
#2005
Incidence and Prevalence of Neuroendocrine Tumors in England
Introduction:
Historically the incidence and prevalence of neuroendocrine tumours (NETs) has been difficult to establish. Studies by Ellis et al in 2006 estimated the incidence of gastroenteropancreatic neuroendocrine tumours (GEP NETs) to be 1.3 per 100,000 per year (incidence hereafter given as cases per 100,000). However, the SEER USA data suggests a four-fold higher incidence, and prevalence of 35 per 100,000.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Genus T
Authors:
Genus T,
Bouvier C,
Wong K,
Srirajaskanthan R,
Rous B,
Keywords:
Neuroendocrine cancer,
prevalence,
incidence,
